Cite
HARVARD Citation
Herbst, R. et al. (n.d.). LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042. Annals of oncology. p. . [Online].